^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SMARCA4 mutation

    i
    Other names: SMARCA4, SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4, Mitotic Growth And Transcription Activator, ATP-Dependent Helicase SMARCA4, Global Transcription Activator Homologous Sequence, Transcription Activator BRG1, Sucrose Nonfermenting-Like 4, BRG1-Associated Factor 190A, Protein Brahma Homolog 1, BRM/SWI2-Related Gene 1, Homeotic Gene Regulator, Brahma Protein-Like 1, Nuclear Protein GRB1, Protein BRG-1, SNF2-Like 4, SNF2-Beta, BAF190A, SNF2L4, BRG1,BAF190, SNF2LB, HSNF2b, MRD16, RTPS2, SNF2B, CSS4, SNF2, SWI2
    Entrez ID:
    6597
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (NCT05286801)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/17/2022
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    TNFA • SMARCB1
    |
    SMARCA4 mutation
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial (NCT05715281)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/26/2023
    Primary completion :
    10/15/2026
    Completion :
    10/15/2026
    SMARCB1
    |
    SMARCA4 mutation
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737)
    Phase 1/2
    Haihe Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    09/08/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    ARID1A • BAP1
    |
    ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation
    |
    HH2853
    A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)
    Phase 2
    Epizyme, Inc.
    Completed
    Last update posted :
    04/29/2024
    Initiation :
    12/22/2015
    Primary completion :
    02/26/2024
    Completion :
    02/26/2024
    CD34 • SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)
    Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) (NCT02114229)
    Phase 2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    05/14/2014
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    SMARCB1
    |
    SMARCA4 mutation
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • topotecan • alisertib (MLN8237) • cyclophosphamide intravenous
    A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma (NCT05495464)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/23/2024
    Initiation :
    11/18/2022
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5
    |
    CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (NCT05538572)
    Phase 1
    Prelude Therapeutics
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    12/27/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B
    |
    KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type
    |
    PRT3645
    Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers (NCT04416568)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    11/28/2023
    Initiation :
    08/14/2020
    Primary completion :
    10/01/2024
    Completion :
    10/01/2025
    SMARCB1
    |
    SMARCA4 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (NCT05407441)
    Phase 1/2
    Susan Chi, MD
    Recruiting
    Last update posted :
    08/22/2023
    Initiation :
    08/10/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2029
    SMARCB1
    |
    SMARCA4 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)
    Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer (NCT03654716)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    08/11/2023
    Initiation :
    11/01/2018
    Primary completion :
    07/17/2023
    Completion :
    07/17/2023
    TP53 • MDM2 • TET2 • SMARCB1 • PPM1D
    |
    TP53 wild-type • MDM2 amplification • TET2 mutation • SMARCA4 mutation • PPM1D mutation
    |
    cytarabine • ALRN-6924
    A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (NCT02601937)
    Phase 1
    Epizyme, Inc.
    Completed
    Last update posted :
    12/27/2021
    Initiation :
    01/07/2016
    Primary completion :
    10/22/2021
    Completion :
    10/22/2021
    SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)